Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9833 in HR+/HER2- Metastatic Breast Cancer with ESR1 Mutation (SERENA-6)
NCT04964934Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of camizestrant in breast cancer, sponsored by AstraZeneca. Started Jun 2021; status: active, not recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04964934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964934.